Polymorphisms and haplotypes in caspases 8 and 9 genes and risk for prostate cancer: A case-control study in cohort of North India

Urologic Oncology: Seminars and Original Investigations

Volumn 30, Issue 6, 2012, Pages 781-789

  George, Ginu P ^a   Mandal, Raju K ^a   Kesarwani, Pravin ^a   Sankhwar, Satya N ^b   Mandhani, Anil ^a   Mittal, Rama D ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

^b KING GEORGE'S MEDICAL UNIVERSITY   (India)

Author keywords

Caspases 8 and 9; Haplotype; Prostate cancer; RFLP; Single nucleotide polymorphisms

Indexed keywords

CASPASE 8; CASPASE 9;

AGED; ALLELE; ARTICLE; BONE METASTASIS; CANCER PATIENT; CANCER RISK; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; DNA POLYMORPHISM; GENE DELETION; GENE INSERTION SEQUENCE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HAPLOTYPE; HETEROZYGOSITY; HETEROZYGOTE; HUMAN; HUMAN TISSUE; INDIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; RISK; SMOKING; STATISTICAL SIGNIFICANCE;

AGED; APOPTOSIS; CASE-CONTROL STUDIES; CASPASE 8; CASPASE 9; COHORT STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; MALE; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84870527613     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2010.08.027     Document Type: Article

References (29)

1. Parkin D.M., Bray F., Ferlay J., et al. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
2. Grimberg A., Cohen P. Growth hormone and prostate cancer: Guilty by association?. J Endocrinol Invest 1999, 22(5):64-73.
3. Fennell D.A. Caspase regulation in non-small-cell lung cancer and its potential for therapeutic exploitation. Clin Can Res 2005, 11:2097-2105.
4. Hengartner M.O. The biochemistry of apoptosis. Nature 2000, 407:770-776.
5. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
6. Park J.Y., Park J.M., Jang J.S., et al. Caspase 9 promoter polymorphisms and risk of primary lung cancer. Hum Mol Genet 2006, 15:1963-1971.
7. Son J.W., Kang H.K., Chae M.H., et al. Polymorphisms in the caspase 8 gene and the risk of lung cancer. Cancer Genet Cytogenet 2006, 169:121-127.
8. Sun T., Gao Y., Tan W., et al. A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers. Nat Genet 2007, 39:605-613.
9. Frank B., Hemminki K., Wappenschmidt B., et al. Association of the CASP10 V410I variant with reduced familial breast cancer risk and interaction with the CASP8 D302H variant. Carcinogenesis 2006, 27:606-609.
10. MacPherson G., Healey C.S., Teare M.D., et al. Association of a common variant of the CASP8 gene with reduced risk of breast cancer. J Natl Cancer Inst 2004, 96:1866-1869.
11. Gangwar R., Mandhani A., Mittal R.D. Caspase 9 and caspase 8 gene polymorphisms and susceptibility to bladder cancer in north Indian population. Ann Surg Oncol 2009, 16:2028.
12. Gleason D.F., Mellinger G.T. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974, 111:58-64.
13. Miller S.A., Dykes D.D., Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucl Acids Res 1988, 16:1215.
14. Hu Z., Li C., Chen K., et al. Single nucleotide polymorphisms in selected apoptotic genes and BPDE-induced apoptotic capacity in apparently normal primary lymphocytes: A genotype-phenotype correlation analysis. J Cancer Epidemiol 2008, 147905.
15. Cohen G.M. Caspases: The executioners of apoptosis. Biochem. J. 1997, 326:1-16.
16. Murphy T.M., Perry A.S., Lawler M. The emergence of DNA methylation as a key modulator of aberrant cell death in prostate cancer. Endocrine-Related Cancer 2008, 15:11-25.
17. Haiman C.A., Garcia R.R., Kolonel L.N., et al. A promoter polymorphism in the CASP8 gene is not associated with cancer risk. Nat Genet 2008, 40:259-260.
18. Wang M., Zhang Z., Tian Y., et al. A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter associated with risk and progression of bladder cancer. Clin Cancer Res 2009, 15:2567-2572.
19. Li C., Zhao H., Hu Z., et al. Genetic variants and haplotypes of the caspase 8 and caspase 10 genes contribute to susceptibility to cutaneous melanoma. Hum Mutat 2008, 29:1443-1451.
20. Yang M., Sun T., Wang L., et al. Functional variants in cell death pathway genes and risk of pancreatic cancer. Clin Cancer Res 2008, 14:3230-3236.
21. Pittman A.M., Broderick P., Sullivan K., et al. CASP8 variants D302H and -652 6N ins/del do not influence the risk of colorectal cancer in the United Kingdom population. Br J Cancer 2008, 98:1434-1436.
22. Bethke L., Sullivan K., Webb E., et al. The common D302H variant of CASP8 is associated with risk of glioma. Cancer Epidemiol Biomarkers Prev 2008, 17:987-989.
23. Rajaraman P., Wang S.S., Rothman N., et al. Polymorphisms in apoptosis and cell cycle control genes and risk of brain tumors in adults. Cancer Epidemiol Biomarkers Prev 2007, 16:1655-1661.
24. Sun T., Miao X., Zhang X., et al. Polymorphisms of death pathway genes FAS and FASL in esophageal squamous cell carcinoma. J Natl Cancer Inst 2004, 96:1030-1036.
25. Zhang X., Miao X., Sun T., et al. Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer. J Med Genet 2005, 42:479-484.
26. Judson R., Stephens J.C., Windemuth A. The predictive power of haplotypes in clinical response. Pharmacogenomics 2000, 1:15-26.
27. Judson R., Stephens J.C. Notes from the SNP versus haplotype front. Pharmacogenomics 2001, 2:1963-1971.
28. Chen H., Cowan M.J., Hasday J.D., et al. Tobacco smoking inhibits expression of pro-inflammatory cytokines and activation of IL-1R-associated kinase, p38, and NF-κB in alveolar macrophages stimulated with TLR2 and TLR4 agonists. J Immunol 2007, 179:6097-6106.
29. Khoury M.J., Flanders W.D. Nontraditional epidemiologic approaches in the analysis of gene-environment interaction: Case-control studies with no controls. Am J Epidemiol 1996, 144:207-213.